Category: Gastroenterology and Endoscopy

Iterative Scopes taps new chief technology officer

Iterative Scopes, a gastroenterology-focused software company, selected Aditya Khosla, PhD, as its chief technology officer.

Cleveland Clinic hospital in Florida receives $5M for digestive center

Cleveland Clinic Weston (Fla.) Hospital received a $5 million donation for research and education at the digestive disease center from Steven Shulman and his wife, Ellen.

Private equity creates ‘big uncertainty’ in gastroenterology, physician says

As private equity’s influence in healthcare continues to grow, its effect on the gastroenterology industry remains murky.

6 colonoscopy, endoscopy updates

Here are six colonoscopy and endoscopy updates Becker’s has reported on since May 5:

20 gastroenterology companies to know 

From device companies to providers, here are 20 gastroenterology-focused companies to know:

5 gastroenterology, endoscopy ASC openings

Here are five gastroenterology- and endoscopy-focused ASCs that have opened or have plans to open that Becker’s has reported on since April 12:

The biggest challenges gastroenterologists are facing

The ebbs and flows of the evolving field of gastroenterology come with a host of challenges, including patients’ stressors and whether to seek funding from private equity.

Gastroenterology device market valued at $9.74B in 2021

The latest report on the global gastroenterology device market estimates a market worth of $9.74 billion in 2021 with an anticipated compound annual growth rate of 8.3 percent from 2022 to 2028, Precision Business Insights reported in June. 

Patients, physicians face challenges with follow-up colonoscopy billing

As policies around billing colonoscopies continue to change, it remains clear patients and physicians have trouble navigating the process.

New AI partnership aims to find best candidates for IBD trials

Providence, Rhode Island-based University Gastroenterology is teaming up with Virgo Surgical Video Solutions to use artificial intelligence to identify patients for inflammatory bowel disease trials.